Balancing needs and resources in medicines delivery

•Download as PPT, PDF•

0 likes•573 views

Irish Pharmaceutical Healthcare Association (IPHA)

Presentation delivered by Mr Shaun Flanagan, Corporate Pharmaceutical Unit, Health Service Executive at the Irish Pharmaceutical Healthcare Association Annual Meeting 2009.

Balancing needs and resources in medicines delivery The Challenge NOW and into the future Shaun Flanagan, Corporate Pharmaceutical Unit

Medicine Supply: Core Principles 2006 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Making Room for Innovation: Finding the Balance 2006 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

2006 Agreement ,[object Object],[object Object],[object Object]

Where are we now? Where are we likely to go?

Projecting the Impact of Demographic Change on the Demand for and Delivery of Healthcare in Ireland ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

2006 -> 2020 (ITEMS 2021) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Limitations of Predictions ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Health system - Challenges ,[object Object],[object Object]

Clinical Care & Quality ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Clinical Care & Quality ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Medicine Supply: Core Principles 2010 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Investment in Innovative medicines ,[object Object],[object Object],[object Object],[object Object],[object Object]

Investment in Innovative medicines ,[object Object],[object Object],[object Object]

Medicines for Orphan Diseases ,[object Object],[object Object],[object Object],[object Object]

Core Principles ,[object Object],[object Object],[object Object]

Financial Headroom ,[object Object],[object Object],[object Object]

Financial Headroom – efficacy in use ,[object Object],[object Object],[object Object]

Adverse drug reactions (ADR) as cause of admission to hospital ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

TORCH: (NEJM 356;8 Feb 22 2007) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

TORCH: (ClinicalTrials.gov number, NCT00268216.) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

TORCH: POST HOC REVIEW OF ADHERENCE DATA ,[object Object],[object Object],[object Object],[object Object],[object Object]

Summary ,[object Object],[object Object],[object Object],[object Object]

Contact Details ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

In a research report by Berdud, M., Drummond, M. and Towse, A. (2018), a reasonable price for an orphan drug was established based on the proposition that rates of returns from investments in developing orphan drugs should be no greater than the industry average (for all drugs). At the 2018 EuHEA conference held in Maastricht, The Netherlands, 11-14 July, Mikel showed (i) how the reasonable price should be established and (ii) how NICE's cost-effectiveness threshold should be adjusted to ensure a reasonable price for an orphan drug. In slides results are discussed and conclusions showed too. Author(s) and affiliation(s): Mikel Berdud, PhD (OHE); Prof. Mike Drummond (University of York); Prof. Adrian Towse (OHE) Conference/meeting: EuHEA 2018 Location: Maastricht, The Netherlands Date: 12/07/2018

Ispor opportunity costs_sks

Office of Health Economics

Disparities in Access to Quality Care

IDS

Access Quality And Affordability How Technology Can Transform Education In ...

Stephen Murgatroyd, PhD FBPsS FRSA

What's hot

Towards a Value Framework for Antibiotics

Office of Health Economics

Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.

Office of Health Economics

Towse NDDP implications for drug development

Office of Health Economics

Lunchtime Seminar with Paula Lorgelly - 14 December 2015

Office of Health Economics

HTA training - Philip Watt, CF Ireland - July 26th 2016

ipposi

Do nice decisions affect decisions in other countries ht ai

Office of Health Economics

JCS PublicationP25lrApluscro_FinalChen Li-Wen (Penny)

Comparing Cancer-Specific Preference-Based Outcome Measures: The Same but Dif...

Office of Health Economics

Multi-indication Pricing: Do we want it? Can we Personalize it?

Office of Health Economics

HTA Training - Prof Michael Barry - July 26th 2016

ipposi

Ispor poster expanding_value_footprint_oncology_treatment_jmf_oct2014

Office of Health Economics

Towse future of CER in US

Office of Health Economics

984 e c__f_j__pf_pMohammed Alshakka

ISPOR Special Task Force on US Value Frameworks: A Non-US Perspective

Office of Health Economics

Understanding Different Stakeholder Requirements Throughout Commercialization

PAREXEL International

Ispor measuring access_pon_nd

Office of Health Economics

Operational Aspects of Independent Reviews for Immune-Oncology Clinical Endpo...

PAREXEL International

Generating Evidence to Drive Patient Access

PAREXEL International

Establishing a Reasonable Price for an Orphan Drug

Office of Health Economics

Ispor opportunity costs_sks

Office of Health Economics

What's hot (20)

Towards a Value Framework for Antibiotics

Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.

Towse NDDP implications for drug development

Lunchtime Seminar with Paula Lorgelly - 14 December 2015

HTA training - Philip Watt, CF Ireland - July 26th 2016

Do nice decisions affect decisions in other countries ht ai

JCS PublicationP25lrApluscro_Final

Comparing Cancer-Specific Preference-Based Outcome Measures: The Same but Dif...

Multi-indication Pricing: Do we want it? Can we Personalize it?

HTA Training - Prof Michael Barry - July 26th 2016

Ispor poster expanding_value_footprint_oncology_treatment_jmf_oct2014

Towse future of CER in US

984 e c__f_j__pf_p

ISPOR Special Task Force on US Value Frameworks: A Non-US Perspective

Understanding Different Stakeholder Requirements Throughout Commercialization

Ispor measuring access_pon_nd

Operational Aspects of Independent Reviews for Immune-Oncology Clinical Endpo...

Generating Evidence to Drive Patient Access

Establishing a Reasonable Price for an Orphan Drug

Ispor opportunity costs_sks

Viewers also liked

Disparities in Access to Quality Care

IDS

Access Quality And Affordability How Technology Can Transform Education In ...

Stephen Murgatroyd, PhD FBPsS FRSA

The Future of Market Access – The Patient PicturePM Society

Using Technology to Increase Medication Adherence

Timothy Aungst, Pharm.D.

Poppy day

Оксана Дева

Health care access and Medicaid in Ohio

Advocates for Ohio's Future

Ohio's Medicaid program made health care available to more people than ever before in 2014, but there's more work to be done. The slides include an update on enrollment and health care access in Ohio, what's next for Ohio's Medicaid program, why personal stories are critical in our efforts to support health care access, and how you can get involved to keep Ohio’s families and communities healthy in the coming months.

4 invocas mark firth debt sale

CCR-interactive

Medication Adherence TECHNOLOGY Brief update 2016Michelle Y. Williams RN PhDc

Medication adherence-01ccd 2

Michelle Perron

M health innovations as a health systems strengthening tool 2014

torooti

Global Trends in e-Health and Medication Adherence by Yuri Quintana, Ph.D. 1...

Harvard Medical School

The future of market access – the local picture PM Society

Future of Market Access – a Pharma PerspectivePM Society

Dimensions of Quality in Healthcare

Dr. Aqeel Ahmed Khan

Viewers also liked (14)

Disparities in Access to Quality Care

Access Quality And Affordability How Technology Can Transform Education In ...

The Future of Market Access – The Patient Picture

Using Technology to Increase Medication Adherence

Poppy day

Health care access and Medicaid in Ohio

4 invocas mark firth debt sale

Medication Adherence TECHNOLOGY Brief update 2016

Medication adherence-01ccd 2

M health innovations as a health systems strengthening tool 2014

Global Trends in e-Health and Medication Adherence by Yuri Quintana, Ph.D. 1...

The future of market access – the local picture

Future of Market Access – a Pharma Perspective

Dimensions of Quality in Healthcare

Similar to Balancing needs and resources in medicines delivery

Webinar 3: Alternative Approaches to Innovative Drug Pricing

Canadian Organization for Rare Disorders

Webinar 3: Alternative Approaches to Innovative Drug Pricing – 12:00pm on Wednesday, May 13, 2020. The third webinar will review Canada’s approach to managing drug prices with approaches used in other jurisdictions. A panel will discuss experiences with oncology therapies, rare disease drugs, and therapies for pandemics and other urgent situations as points of reference toward evolving alternatives to the proposed PMPRB guidelines. Panel: Martina Garau, Director, Office of Health Economics, UK; Sandra Anderson, Senior VP, Innomar Strategies PG Forest, Director, School of Public Policy, University of Calgary Durhane Wong-Rieger, President & CEO, CORD Moderator: Bill Dempster, 3Sixty Public Affairs

Projected impact of demographic change on the demand for pharmaceuticals in I...

Irish Pharmaceutical Healthcare Association (IPHA)

ABPI white paperEuroBioForum

Patient support programmes within medicines optimisation – the pros and consPM Society

Improving Quality And Reducing Cost In Healthcare The Role Of Information And...healthcareisi

Andrew Powrie-Smith (EFPIA) for European Patients' Rights Day

Cittadinanzattiva onlus

Defining the Outcomes that Matter for Perioperative Pain Medicine

Colin McCartney

2014 01 Boris Azais - How Pharmaceutical companies are transforming for the...

Boris Azaïs

Μάκης Παπαταξιάρχης, 3rd Health Innovation Conference

Starttech Ventures

Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...Canadian Organization for Rare Disorders

Future Challenges of Clinical Development; a View from the CRO - Hani ZakiTTC, llc

Lexington Health Practice 'The future of Market Access' Interactive Pamphlet

Emily Stevenson

Lexington Health Practice recently held a breakfast event to discuss the future for market access in England. The breakfast, the first in a series, examined the Health Technology Appraisal (HTA) environment and facilitated a discussion amongst individuals who work closely with and amongst the pharmaceutical industry, examining how the mechanisms in place can be improved to ensure equitable access to medicines.

OHE Lecturing for Professional Training at International Centre of Parliament...

Office of Health Economics

On 7th November 2018, Bernarda Zamora delivered a pro bono lecture to professionals from diverse countries enrolled at the Professional Certificate in Strategic Planning organised by the International Centre of Parliamentary Studies. Author(s) and affiliation(s): Bernarda Zamora, Office of Health Economics Conference/meeting: Professional Certificate in Strategic Planning organised by the International Centre of Parliamentary Studies Location: Conference Centre, London Date: Conference Centre, London

Consumer health: time for a regulatory re-think?

The Economist Media Businesses

Big Data and Stratified Medicine

Office of Health Economics

Neil Fraserichil

The Impact Global Pharma Cost Containment Methods in APAC

QuintilesIMS Asia Pacific

The value of generics and biosimilar drugs

Pharmacy @ Institut Kanser Negara

Hbp Stategy Hypertension Management Initiative Feb07primary

Similar to Balancing needs and resources in medicines delivery (20)

Webinar 3: Alternative Approaches to Innovative Drug Pricing

Projected impact of demographic change on the demand for pharmaceuticals in I...

ABPI white paper

Patient support programmes within medicines optimisation – the pros and cons

Improving Quality And Reducing Cost In Healthcare The Role Of Information And...

Andrew Powrie-Smith (EFPIA) for European Patients' Rights Day

Defining the Outcomes that Matter for Perioperative Pain Medicine

2014 01 Boris Azais - How Pharmaceutical companies are transforming for the...

Μάκης Παπαταξιάρχης, 3rd Health Innovation Conference

Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...

Future Challenges of Clinical Development; a View from the CRO - Hani Zaki

Lexington Health Practice 'The future of Market Access' Interactive Pamphlet

OHE Lecturing for Professional Training at International Centre of Parliament...

Consumer health: time for a regulatory re-think?

Big Data and Stratified Medicine

Neil Fraser

The Impact Global Pharma Cost Containment Methods in APAC

The value of generics and biosimilar drugs

Hbp Stategy Hypertension Management Initiative Feb07

More from Irish Pharmaceutical Healthcare Association (IPHA)

Session 2 Panel DiscussionIrish Pharmaceutical Healthcare Association (IPHA)

The Healthcare Funding and Delivery Challenge in Ireland

Irish Pharmaceutical Healthcare Association (IPHA)

Contribution of a world-class regulatory system to the future of the pharmace...

Irish Pharmaceutical Healthcare Association (IPHA)

The Value of Medicines and Vaccines to Irish patients and the Irish economy

Irish Pharmaceutical Healthcare Association (IPHA)

How to ensure the best utilisation of healthcare resources in Ireland - the e...

Irish Pharmaceutical Healthcare Association (IPHA)

The role of Health Technology Assessment and current developments in Ireland

Irish Pharmaceutical Healthcare Association (IPHA)

The Development of National Programmes of Care in Ireland

Irish Pharmaceutical Healthcare Association (IPHA)

The role of clinical research in securing the future of the industry in Ireland

Irish Pharmaceutical Healthcare Association (IPHA)

The IDA Ireland strategy for the pharmaceutical industy in Ireland

Irish Pharmaceutical Healthcare Association (IPHA)

The Development of a New MedicineIrish Pharmaceutical Healthcare Association (IPHA)

Pharmaceutical Healthcare Facts and Figures 2010

Irish Pharmaceutical Healthcare Association (IPHA)

Consumer Driven Healthcare

Irish Pharmaceutical Healthcare Association (IPHA)

Mens use of health services; a no man's land?

Irish Pharmaceutical Healthcare Association (IPHA)

The health challenges facing Irish society

Irish Pharmaceutical Healthcare Association (IPHA)

The challenges facing the pharmaceutical industry through to 2020

Irish Pharmaceutical Healthcare Association (IPHA)

IPHA Healthcare Facts And Figures 2009

Irish Pharmaceutical Healthcare Association (IPHA)

Driven By Health: Pharmaceutical Industry Corporate Responsibility in Ireland

Irish Pharmaceutical Healthcare Association (IPHA)

More from Irish Pharmaceutical Healthcare Association (IPHA) (17)

Session 2 Panel Discussion

The Healthcare Funding and Delivery Challenge in Ireland

Contribution of a world-class regulatory system to the future of the pharmace...

The Value of Medicines and Vaccines to Irish patients and the Irish economy

How to ensure the best utilisation of healthcare resources in Ireland - the e...

The role of Health Technology Assessment and current developments in Ireland

The Development of National Programmes of Care in Ireland

The role of clinical research in securing the future of the industry in Ireland

The IDA Ireland strategy for the pharmaceutical industy in Ireland

The Development of a New Medicine

Pharmaceutical Healthcare Facts and Figures 2010

Consumer Driven Healthcare

Mens use of health services; a no man's land?

The health challenges facing Irish society

The challenges facing the pharmaceutical industry through to 2020

IPHA Healthcare Facts And Figures 2009

Driven By Health: Pharmaceutical Industry Corporate Responsibility in Ireland

Recently uploaded

Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists

Saeid Safari

For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls

Savita Shen $i11

How to Give Better Lectures: Some Tips for Doctors

LanceCatedral

ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx

Swetaba Besh

Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx

Dr. Rabia Inam Gandapore

KDIGO 2024 guidelines for diabetologists

د.محمود نجيب

Are There Any Natural Remedies To Treat Syphilis.pdf

Little Cross Family Clinic

NVBDCP.pptx Nation vector borne disease control program

Sapna Thakur

Ophthalmology Clinical Tests for OSCE exam

KafrELShiekh University

Novas diretrizes da OMS para os cuidados perinatais de mais qualidade

Prof. Marcus Renato de Carvalho

Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva. Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade. Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal. Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural. Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis. É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais. O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada. Recomendamos muito. Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos. Esta publicação só está disponível em inglês até o momento. Prof. Marcus Renato de Carvalho www.agostodourado.com

Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences

Yodley Lifesciences

micro teaching on communication m.sc nursing.pdf

Anurag Sharma

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...

i3 Health

i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource. This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and Associate Division Director for Ambulatory Operations The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma. STATEMENT OF NEED Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL. Target Audience Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL). Learning Objectives 1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL 2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults 3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection

Light House Retreats: Plant Medicine Retreat Europe

Lighthouse Retreat

263778731218 Abortion Clinic /Pills In Harare ,

sisternakatoto

263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/

Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh

Dr. Madduru Muni Haritha

Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.

Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...

Savita Shen $i11

Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx

Dr. Rabia Inam Gandapore

MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf

Jim Jacob Roy

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?

bkling

Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.

Recently uploaded (20)

Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists

For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls

How to Give Better Lectures: Some Tips for Doctors

ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx

Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx

KDIGO 2024 guidelines for diabetologists

Are There Any Natural Remedies To Treat Syphilis.pdf

NVBDCP.pptx Nation vector borne disease control program

Ophthalmology Clinical Tests for OSCE exam

Novas diretrizes da OMS para os cuidados perinatais de mais qualidade

Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences

micro teaching on communication m.sc nursing.pdf

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...

Light House Retreats: Plant Medicine Retreat Europe

263778731218 Abortion Clinic /Pills In Harare ,

Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh

Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...

Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx

MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?